Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.

Authors:
Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L and 6 more

Journal:
JAMA Dermatol

Publication Year: 2022

DOI:
10.1001/jamadermatol.2022.1185

PMCID:
PMC9096693

PMID:
35544084

View on PubMed View on PMC View Publisher
Journal Information

Full Title: JAMA Dermatol

Abbreviation: JAMA Dermatol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Dermatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics.
Haggenmüller S; Schmitt M; Krieghoff-Henning E and 29 more (2024) - Transparency Score: 1/6
Incidence and Factors Associated With Second Primary Invasive Melanoma in Norway.
Ghiasvand R; Green AC; Veierød MB and 1 more (2024) - Transparency Score: 1/6
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A; Alabas OA; Yiu ZZN and 8 more (2024) - Transparency Score: 1/6
Risk of Suicide and Psychiatric Disorders Among Isotretinoin Users: A Meta-Analysis.
Tan NKW; Tang A; MacAlevey NCYL and 2 more (2024) - Transparency Score: 2/6
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analy…
Paller AS; Silverberg JI; Cork MJ and 10 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"UCB Pharma; NIHR Manchester Biomedical Research Centre"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025